Neurological complex diseases include Alzheimer’s and Parkinson’s disease, neuromuscular disorders such as amyotrophic lateral sclerosis (ALS), and psychiatric conditions including depressive disorders and schizophrenia which are all the result of multifactorial interactions.
It is only recently through next-generation sequencing (NGS) studies that the full genomic complexity of neurological diseases is being revealed. The interplay between heritable and nonheritable mutations, epigenetics, and other factors requires NGS-level analyses to increase our understanding. Illumina has the array and NGS tools needed to make genomic neuroscience research possible.
TruSeq Targeted RNA Expression Neurodegeneration Panel: This assay offers an RNA sequencing solution for studying neurodegenerative and neurotoxic pathways such as those implicated in Alzheimer’s disease.
Infinium PsychArray BeadChip: This array enables researchers to evaluate genetic variants associated with common psychiatric disorders.
Kailos TargetRich PGxComplete: This enrichment-based targeted sequencing research panel covers 43 genes associated with responses to ~100 medications.
Kailos Blue Analytics provide sequencing quality assessment, alignment, and variant calling in output formats suitable for use with a variety of reporting solutions.